Noncoding RNA: Aging well with Norad
In mice, deleting a long noncoding RNA drives premature aging.
- The Weizmann Institute of Science, Israel
Aging is a complex process that affects most living organisms. Over a century of research has revealed that many different intrinsic and extrinsic factors contribute to our bodies growing old, but we are still a long way from a full understanding of all the mechanisms at play. Recent research has implicated molecules that do not code for proteins in this process, such as long noncoding RNAs. For instance, many of these so-called 'lncRNAs' are expressed differently in patients with age-related disorders, such as various forms of neurodegenerative disease and cancer (Rinn and Chang, 2012).
Now, in eLife, Joshua Mendell of the University of Texas Southwestern Medical Center (UTSW) and colleagues – including Florian Kopp as first author – report that losing the long noncoding RNA Norad accelerates aging in mice (Kopp et al., 2019). Previous studies have shown that Norad is highly conserved in mammals, and that it is abundant in most human cells (Lee et al., 2016; Tichon et al., 2016). The production of Norad increases in response to DNA damage and it helps preserve the genetic information as cells divide. Norad is mainly found in the cytoplasm, where it can bind two PUMILIO proteins (PUM1 and PUM2) that regulate a variety of targets in the cell, including some involved in cell growth and division (Figure 1). Yet, it was unknown what deleting Norad would entail at the level of an organism.
Figure 1
The Norad-PUMILIO axis.
The long noncoding RNA Norad (top) can bind to the PUMILIO proteins PUM1 (pale blue) and PUM2 (pale green) and repress their activity (Lee et al., 2016; Tichon et al., 2016). PUM1 and PUM2 also inhibit each other, and they may repress Norad (dotted inhibitory arrow; Goldstrohm et al., 2018). In mice that are genetically engineered to lack Norad or to overproduce PUM2, PUMILIO proteins become overactive and strongly inhibit molecules that prevent damage to mitochondria (bottom dark and light gray structure), as well as molecules that prevent cells from acquiring the wrong number of chromosomes (aneuploidy). As a result, these mice show accelerated aging (bottom; Kopp et al., 2019).
To investigate this question, Kopp et al. – who are based at UTSW, the Nationwide Children's Hospital and Ohio State University – engineered mice that lacked Norad. As the mutant animals grew, they displayed signs of premature aging: their fur thinned down and grayed faster; their spine showed the abnormal curvature associated with old age; their fat reserves dwindled more quickly; and they died earlier. Mice lacking Norad also exhibited several cellular hallmarks of aging (López-Otín et al., 2013). Many of their cells had the wrong number of chromosomes (as previously seen in Norad-deficient human cells), as well as mitochondria that were showing defects. This was associated with the repression of PUMILIO targets that keep mitochondria working properly. Strikingly, mice engineered to over-produce PUM2 had similar characteristics, clearly indicating that the hyperactivity of PUMILIO drives the symptoms associated with a lack of Norad (Figure 1).
On the flipside, a recent study in humans showed that halving the dose of PUM1 leads to developmental delay and seizures (Gennarino et al., 2018), and reducing the amount of PUM1, PUM2, or both results in smaller body size (Lin et al., 2019). These results suggest that mammals must maintain the activity of PUMILIO proteins within a narrow range in order to remain healthy. In fact, the levels of PUM2 proteins in bulk tissues are indistinguishable between control mice and animals that overexpress Pum2. Furthermore, in both Norad-deficient and Pum2-overexpressing mice, most PUMILIO targets are only affected very mildly, yet the animals exhibit striking phenotypes. Kopp et al. argue that repressing many PUMILIO targets at the same time, even weakly, may trigger the physiological damages observed in these rodents.
Still, it may also be possible that when the Norad-PUMILIO axis is disrupted, certain cells or tissues are more likely to stop working properly, which in turn creates a snowball effect for the whole organism. For instance, the expression of Norad is highest in the human brain, but it decreases with age in a region that acts as a reservoir to regenerate brain cells (Barry et al., 2015). In simpler organisms, such as the worm C. elegans, the nervous system acts on other tissues to coordinate pathways that keep proteins in their normal conformation, but these mechanisms become defective with age (van Oosten-Hawle and Morimoto, 2014). It remains unclear whether the nervous system performs such roles in mammals; yet, these results raise the possibility that interactions between Norad and PUMILIO are needed in specific tissues to ward off the effects of age.
Norad is PUMILIO’s preferred target, and has several binding sites that are recognized by these proteins. This suggests that this lncRNA can bind a large number of PUMILIO proteins at any given moment, but it is still unclear whether Norad tempers the activity of PUM1 and PUM2 simply by competing with other targets of PUMILIO, or if another mechanism is at play (Goldstrohm et al., 2018; Tichon et al., 2018).
Curiously, Norad is only found in mammals, whereas the PUMILIO proteins are found in all eukaryotes; it is therefore possible that RNAs with different sequences also buffer the activity of PUMILIO in other species. It remains to be seen how and why mammalian cells rely on Norad to tame the activity of these proteins, as opposed to other types of regulatory mechanisms. Ultimately, the work by Kopp et al. sets the ground for further enquiries into the role of noncoding RNAs and RNA-binding proteins in aging, which could potentially yield new therapeutic approaches for diseases brought by old age.
References
-
Post-transcriptional regulatory functions of mammalian Pumilio proteinsTrends in Genetics 34:972–990.https://doi.org/10.1016/j.tig.2018.09.006
-
Genome regulation by long noncoding RNAsAnnual Review of Biochemistry 81:145–166.https://doi.org/10.1146/annurev-biochem-051410-092902
Article and author information
Author details
Filipa Carvalhal Marques
Publication history
Copyright
© 2019, Marques and Ulitsky
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,540
- views
-
- 211
- downloads
-
- 7
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Noncoding RNA: Aging well with Norad
eLife 8:e45974.
https://doi.org/10.7554/eLife.45974
Further reading
-
- Cell Biology
- Chromosomes and Gene Expression
Meiotic crossover recombination is essential for both accurate chromosome segregation and the generation of new haplotypes for natural selection to act upon. This requirement is known as crossover assurance and is one example of crossover control. While the conserved role of the ATPase, PCH-2, during meiotic prophase has been enigmatic, a universal phenotype when pch-2 or its orthologs are mutated is a change in the number and distribution of meiotic crossovers. Here, we show that PCH-2 controls the number and distribution of crossovers by antagonizing their formation. This antagonism produces different effects at different stages of meiotic prophase: early in meiotic prophase, PCH-2 prevents double-strand breaks from becoming crossover-eligible intermediates, limiting crossover formation at sites of initial double-strand break formation and homolog interactions. Later in meiotic prophase, PCH-2 winnows the number of crossover-eligible intermediates, contributing to the designation of crossovers and ultimately, crossover assurance. We also demonstrate that PCH-2 accomplishes this regulation through the meiotic HORMAD, HIM-3. Our data strongly support a model in which PCH-2’s conserved role is to remodel meiotic HORMADs throughout meiotic prophase to destabilize crossover-eligible precursors and coordinate meiotic recombination with synapsis, ensuring the progressive implementation of meiotic recombination and explaining its function in the pachytene checkpoint and crossover control.
-
- Cancer Biology
- Chromosomes and Gene Expression
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.
